A Phase 2 interventional study of FMT combined with QL1706 plus Bevacizumab in Advanced Hepatocellular Carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular — 14 open to participants now, 14 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Carcinoma, Hepatocellular.
Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, this one is the 14th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 13th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →14 of the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Ages 18–75
Nanjing Tianyinshan Hospital · Sites in China
Ages 18+
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 1 · Phase 4 1
First in 2023; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 14 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 499 studies on the registry; 298 are open to participants now.
43 studies in Carcinoma, Hepatocellular by Tianjin Medical University Cancer Institute and Hospital: 27 open now, 31 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 43 studies in Carcinoma, Hepatocellular by Tianjin Medical University Cancer Institute and Hospital, this one is the 37th largest by planned enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2026, is one of 30 in phase 2, reaches primary completion later than 29 of the 30 other live ones, and was the 43rd registered.
Tianjin Medical University Cancer Institute and Hospital’s Carcinoma, Hepatocellular studies by the year they started, since 2011.
4 of the studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976568Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | 2027-09-01 |
| NCT07115550Huai'an First People's HospitalA Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | 2027-08-26 |
| NCT06884982Northern Jiangsu People's HospitalAn Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib | 2027-09-30 |
| NCT07776080Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, from their registry updates:
Among Tianjin Medical University Cancer Institute and Hospital’s 43 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
Iparomlimab and Tuvonralimab (QL1706), constitute a bifunctional antibody target both programmed death-1 and cytotoxic T lymphocyte-associated protein-4.
The purpose of this pilot study is to assess the efficacy and safety of fecal microbiota transplantation (FMT) combined with QL1706 Plus Bevacizumab as first-line treatment for advanced HCC.
The primary objective is to test the efficacy of FMT combined with QL1706 Plus Bevacizumab, as measured by objective response rate (ORR).
The secondary objectives are to assess and test the safety of FMT in combination with QL1706 Plus Bevacizumab as first-line treatment for advanced HCC as measured by Disease Control Rate (DCR), Duration of Response(DoR), Progression-Free Survival (PFS), Overall Survival (OS), and Adverse Events (AEs).
Furthermore, this study aims to investigate multi-omics prognosis prediction biomarkers and their associated mechanisms.
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FMT combined with QL1706 plus Bevacizumab
Drug: FMT combined with QL1706 plus Bevacizumab
Drug pages: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral Fecal Microbiota Transplantation (FMT) capsules: Full-dose FMT (80-100g) will be administered on Days 0,28, and 49. Iparomlimab and Tuvonralimab (QL1706): QL1706 will be administered intravenously at a dose of 7.5 mg/kg, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days. Bevacizumab: Bevacizumab will be administered intravenously at a dose of 15 mg/kg body weight, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days.
Objective response rate (ORR)
To assess the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to Objective Response Rate (ORR).
Time frame: Every 9 weeks from the first dose of FMT administration until the first documented disease progression, death or study completion, up to approximately 1 year.
Disease Control Rate (DCR)
To observe and evaluate the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for unresectable or metastatic HCC with respect to Disease Control Rate (DCR) determined by the radiologist per mRECIST v1.1 criteria.
Time frame: Every 9 weeks from the first dose of FMT administration until the first documented disease progression, death or study completion, up to approximately 1 year.
Progression-Free Survival (PFS)
Time from the start of treatment to the first documented disease progression as determined by the radiologist per mRECIST/ RECIST v1.1 criteria or death from any cause.
Time frame: From first study treatment until the first documented disease progression or death from any cause, whichever occurs first, up to approximately 1 year.
Overall Survival (OS)
To observe and evaluate the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to overall survival (OS).
Time frame: Starting from the time of treatment until death from any cause assessed from the date of the first intervention up to 24 months.
Adverse events (AEs)
To observe and evaluate the safety of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to adverse events (AEs) AEs will be graded according to NCI-CTCAE V5.0 Safety assessments will be performed from baseline through 30 days (±7 days) after the last dose of study treatment
Time frame: 30 days
Changes in patient gut microbiome composition following FMT
Changes in patient gut microbiome will be determined by analysis of gut bacterial composition in patient stool samples at baseline and post-FMT
Time frame: At baseline (prior to the first FMT administration), before QL1706 plus bevacizumab administration on Days 6,27, and 48, and after the third administration (approximately 9 weeks after FMT initiation).
Multi-Omics prognosis biomarker Profiles
Changes from baseline in prespecified metabolomic and immune-related biomarkers measured using metabolomic analysis and immunological assays, respectively, and their associations with clinical and associated mechanisms.
Time frame: At baseline (prior to the first FMT administration), before QL1706 plus bevacizumab administration on Days 6,27, and 48, and after the third administration (approximately 9 weeks after FMT initiation).
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.
Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 36 months is below that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iparomlimab/Tuvonralimab · Bevacizumab
Tianjin Medical University Cancer Institute and Hospital →